Chapter 8 · Module 8

Proarrhythmia, Drug Interactions, and Special Populations

QT prolongation and torsades de pointes, key drug interactions, renal dosing, and special populations

Drug-Induced QT Prolongation and Torsades de Pointes

Risk Factors -- Amplify Torsades de Pointes Risk

When QT Prolongation Becomes Dangerous

Female sex (70% of drug-induced torsades de pointes)
Hypokalemia and hypomagnesemia -- correct before and during therapy
Bradycardia and pauses -- torsades de pointes is pause-dependent
Corrected QT interval over 500 ms -- stop or reduce the offending drug
Multiple QT-prolonging drugs -- avoid combinations (Class Ia + Class III, antiarrhythmics + fluoroquinolones, azoles, antipsychotics)
Structural heart disease, left ventricular hypertrophy

Acute Management

Torsades de Pointes Protocol

Step 1: Withdraw offending drug immediately
Step 2: Intravenous magnesium sulfate -- first-line regardless of serum level
Step 3: Correct electrolytes -- target K+ at or above 4.5 mEq/L
Step 4: Increase heart rate -- isoproterenol infusion or temporary pacing at 90 to 110 beats per minute
Step 5: Defibrillate if degenerates to ventricular fibrillation
Do NOT give calcium in acquired torsades de pointes

Key Antiarrhythmic Drug Interactions

Combination	Clinical Consequence	Management
Amiodarone + warfarin	International normalized ratio rises 30 to 50%; bleeding risk	Reduce warfarin dose by one-third; monitor weekly x 4 to 8 weeks; persists after amiodarone stopped
Amiodarone + digoxin	Digoxin levels double; toxicity risk	Halve digoxin dose; recheck levels within 1 to 2 weeks
Amiodarone + simvastatin or lovastatin	Statin levels rise; myopathy and rhabdomyolysis risk	Avoid simvastatin above 20 mg; prefer pravastatin or rosuvastatin
Amiodarone + flecainide	Flecainide levels rise; QRS widening; ventricular tachycardia risk	Reduce flecainide dose by 50%; monitor electrocardiogram
Sotalol + diuretics	Hypokalemia amplifies QT prolongation; torsades de pointes risk	Maintain K+ at or above 4.5 mEq/L; monitor electrolytes regularly
Dofetilide + verapamil, cimetidine, or trimethoprim	Dofetilide levels rise sharply; dangerous QT prolongation	All three are absolutely contraindicated with dofetilide

Renal Impairment and Special Populations

Renal Impairment

Dose Adjustment Required

Sotalol: 100% renally eliminated; contraindicated if creatinine clearance below 40 mL/min
Dofetilide: 80% renally eliminated; four-tier dose adjustment; contraindicated if creatinine clearance below 20 mL/min
Digoxin: 70 to 80% renally eliminated; narrow therapeutic index; reduce proportionally
Procainamide: renally eliminated; reduce dose and frequency in renal impairment
Flecainide: 30% renal; reduce when creatinine clearance below 35 mL/min

Renal Impairment

Safe Without Renal Adjustment

Amiodarone: primarily hepatic clearance; safest antiarrhythmic in severe chronic kidney disease
Lidocaine: primarily hepatic; no intravenous renal dose adjustment
Mexiletine: approximately 90% hepatic; minor consideration in severe chronic kidney disease only

Pregnancy

Safe vs. Avoid

Adenosine -- safest; first-line acute supraventricular tachycardia; negligible fetal exposure
Beta-blockers -- relatively safe; metoprolol preferred over atenolol
Digoxin -- relatively safe; also treats fetal supraventricular tachycardia via placenta
Direct-current cardioversion -- safe at any gestational age
Amiodarone -- AVOID; neonatal hypothyroidism (iodine), intrauterine growth restriction; use only for life-threatening refractory arrhythmia

Elderly Patients

Key Prescribing Rules

Start at half the standard adult dose; uptitrate cautiously
Calculate renal function formally -- serum creatinine alone underestimates impairment
Corrected QT interval monitoring mandatory at initiation and after dose changes
Digoxin target: 0.5 to 0.8 nanograms per milliliter (lower than historical targets)
Review all co-medications for QT-prolonging agents (polypharmacy risk)
Annual amiodarone monitoring more critical in elderly than younger patients